ARTICLE
Systemic lupus erythematosus (SLE) is an auto immune disorder mediated by the immune complex and characterised by its protean clinical mani festation and multisystemic involvement (Mak 2007a) . Neuropsychiatric manifestation of SLE (NPSLE) is one of the major and most damag ing presentations. It comprises a wide range of neurological syndromes affecting the central, peripheral and autonomic nervous systems, as well as psychiatric syndromes. In view of the diverse clinical manifestation of NPSLE, the American College of Rheumatology research committee devised a nomenclature which gives case defini tions for 19 neuropsychiatric syndromes in SLE (ACR Ad Hoc Committee on Neuro psychiatric Lupus Nomenclature 1999) (Box 1). Albeit compre hen sive, none of the syndromes described are specific to SLE and, in fact, nonSLE causes such as complications of lupus therapy, infection of the central nervous system (CNS), metabolic dys function and drug intoxication may contribute to them. Hence, these complications must be excluded before being ascribed to the underlying immuno pathogenic mechanisms (Mak 2007b) .
Although overt psychiatric symptoms are often clinically obvious, subtle changes such as mild cognitive impairment are often left unnoticed. This underscores the need for careful and robust clinical assessment tools which help identify these clinically important psychopathologies. In addition, how psychiatrists formally diagnose and evaluate a wide variety of lupusrelated psychiatric syndromes and their impacts by using validated assessment instruments and ultimately manage these syndromes in conjunction with rheumatologists needs to be addressed.
This article reviews the immunopathogenesis, clinical manifestation and therapeutic options for NPSLE, and highlights the indispensable role of psychiatrists working with rheumatologists in the collaborative management of these conditions.
Clinical implications of neuropsychiatric systemic lupus erythematosus
Systemic lupus erythematosus (SLE) is a disorder which can affect the central nervous system and result in a broad range of psychiatric syndromes such as psychosis, mood disorders, acute confusion and cognitive dysfunction. Despite the robust nomen clature of neuropsychiatric SLE (NPSLE), psychiatric syndromes in patients are often nonspecific and may be secondary to concurrent nonSLErelated conditions and complications of medical therapies. Although the exact immunopathological mecha nism for psychiatric presentation remains elusive, prompt exclusion of other factors contributing to the psychiatric symptoms coupled with effective assessment strategies and management with immunosuppression and psychiatric therapy are imperative. Psychiatrists and rheumatologists must work in close liaison to identify, treat and prognosticate patients with psychiatric syndromes in order to improve their quality of life, vocational aptitude and, ultimately, survival.
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Pathogenesis
Regarding the nomenclature of NPSLE, clinical manifestation is divided into diffuse and focal syn dromes, largely depending on the anatom ical sites of the CNS pathology (Fig. 1 (Jentsch 1999) . The exact reason why antiNMDA receptor anti bodies can lead to such diffuse NPSLE syndromes is not clear, although antagonisation of NR2 receptors has been shown to induce apoptosis of neurons and subsequent neuronal injury in a way reminiscent of excitatory aminoacid toxicity (Lipton 1994) . Antiphospholipid antibodies are associated with focal neurological manifestations such as cerebro vascular diseases (Petri 2007) . Box 2 summarises the autoantibodies involved in NPSLE.
BOx 2 Autoantibodies involved in NPSLE
Anti-ribosomal P antibodies Depression-impaired global cognitive functioning (Kozora 2007) Several lines of evidence have demonstrated that serum proinflammatory cytokines are involved in depression in SLE. For example, patients with SLE and depression have elevated serum levels of interleukin (IL)1, IL6, IL2, tumour necrosis factor (TNF)α and interferon (IFN)α (Maes 1995) . Figure 2 summarises the roles of antibodies and cytokines in major neuropsychiatric symptoms and Box 3 lists the changes that occur.
Therapeutic interventions
Treatment options for NPSLE are very limited, as therapy mainly comprises highdose cortico steroids plus an immunosuppressive agent as an induction, followed by switching to a less toxic immunosuppressive agent and lower dose of corticosteroid as maintenance.
Only one small randomised controlled trial has been published comparing intravenous methy lprednisolone and intravenous cyclophosphamide as treatments for NPSLE (Baca 1999) . The study found that significantly more patients responded to treatment in the cyclo phosphamide group compared with the methylprednisolone group.
Apart from immunosuppressive therapies for NPSLE, auxiliary treatments such as anti psychotic, antianxiolytic and antiepileptic agents are often required for controlling symptoms such as psychosis, anxiety and seizures.
Cognitive impairment and lupus
Cognitive impairment is one of the most common NPSLE syndromes, occurring in 20-80% of patients with lupus (Hanly 2005) . The common cognitive abnormalities associated with NPSLE and their expected findings in neuropsychological tests are summarised in Table 1 .
Assessment
As yet, no single bedside screening test is available, as the MiniMental State Examination (MMSE) was shown to be unhelpful in assessing neuropsychiatric manifestations in patients with SLE (Hanly 2005) . Poole et al (2006) found that cognitive deficits were better assessed by performancebased tests of disability rather than a selfreport.
Brain imaging
Similar to schizophrenia, executive dysfunctions such as difficulty in multitasking, organisation and planning are common in NPSLE (Hanly 2005) . In contrast to schizophrenia, the understanding of cognitive dysfunction did not evolve from the traditional 'lesionbased' approach, as earlier magnetic resonance imaging (MRI) findings were either nonspecific or negative.
Diffusion tensor imaging has revealed early changes in the frontal lobe, genu corpus callosum and anterior internal capsule of patients with NPSLE . Monastero et al (2001) found that changes in psychiatric comorbidity such 
Cognitive rehabilitation
Cognitive rehabilitation should also be considered, as it was shown to be promising in patients with schizophrenia and cognitive dysfunction (Wykes 1999 ). Since cognitive impairment pertaining to NPSLE is heterogeneous, one approach to cognitive rehabilitation is to focus on subgroups of patients with specific cognitive abnormalities (e.g. of memory and attention). Larger, controlled trials of cognitive rehabilitation are required to identify specific and effective treatment strategies, longterm outcomes and costeffectiveness of treatment.
Psychosis and lupus
Appenzeller et al (2008) conducted a longitudinal study of patients with SLE for 9 years and identified primary psychotic disorder in 17% of the cohort. Of the patients presenting with primary psychotic disorder, 66% of cases were related to NPSLE, 31% were associated with corticosteroids and 3% were related to neither NPSLE or medication. Psychosis secondary to SLE at disease onset occurred in 21% of patients presenting with primary psychotic disorder and 45% of cases were associated with positive antiphospholipid antibodies.
Psychotic symptoms in SLE
Case study: Corticosteroidinduced psychosis A 19yearold woman was diagnosed with SLE when she presented with arthralgia, malar rash and subsequent diffuse progressive glomerulonephritis. Aggressive immunosuppression comprising intra venous pulse methylprednisolone followed by oral prednisolone and cyclophosphamide was given.
Although her lupus activity was under control, she started to suffer from insomnia and mania. She accused somebody of following and harming her. She had no visual hallucinations, and neurological examination revealed no focal deficit. Thorough metabolic and infection screening was negative and no abnormalities were shown on brain MRI. The diagnosis of corticosteroidinduced psychosis was made and a subsequent prednisolone taper was accompanied by a progressive improvement of her psychotic symptoms over the next 3 weeks. Adjunctive antipsychotics were titrated to zero over a further 2 months.
Cases similar to that of the young woman described above are often referred to psychiatrists. In referrals of young people with a first episode of psychosis it is important to rule out physical disorders such as SLE (Fernandez 2007) . The main clinical features of psychosis in NPSLE are acute delusions and hallucinations. As the typical age at presentation of NPSLErelated psychosis is in the early 20s, it is often difficult to differentiate it from schizophreniform psychosis. Corticosteroids also contribute to psychosis through ischaemia and subsequent hippocampal damage (Wolkowitz 1997) . Table 2 summarises the differences between psychosis related to NPSLE and to cortico steroids.
Antipsychotics and their side-effects
Antipsychotic medication commonly used in schizophrenia can also be given to patients with NPSLE. Lupusrelated bodily changes often affect the pharmacokinetics and pharmacodynamics of antipsychotic drugs, leading to sideeffects that can be persistent and disabling. Chlorpromazine, for example, is well known to cause druginduced lupus. It may aggravate photosensitivity and complicate the existing manifestations of lupus (Harth 1996) . Although recent studies have indicated that the new atypicals may have a more favourable sideeffect profile, agranulocytosis from atypical antipsychotics such as olanzapine has been reported (Su 2007) . Research addressing the use of firstgeneration antipsychotics in people with lupus and psychosis is sparse. These drugs are not recommended because they may exacerbate NPSLEassociated movement disorders (Nishimura 2003) .
No data are yet available from controlled trials regarding the efficacy and safety of second generation antipsychotics. As stroke is one of the NPSLE syndromes, risperidone and olanzapine should be avoided. These drugs are a known risk factor for cerebrovascular adverse events in elderly patients without SLE (Herrmann 2005) . Quetiapine and sulpiride are recommended, as there are no reports of adverse effects in individuals with NPSLE.
In severe NPSLE, pulsed intravenous cyclo phospha mide has produced significant improve ment in psychotic symptoms (Bodani 2003) . The medication was well tolerated in adult and paediatric patients.
Non-pharmacological interventions
Research into nonpharmacological treatment for NPSLEassociated psychosis is limited. Although there is compelling evidence to support the use of cognitive-behavioural therapy (CBT) in modifying delusional beliefs and controlling hallucinations in people with schizophrenia (Garety 1994; Kuipers 1997) , no study has assessed the effect of CBT on patients with NPSLEassociated psychosis; however, the same principles can be applied.
Clinicians should address the nature of untreated SLErelated psychosis and its negative impact on both patient and caregivers if not treated. Psychoeducation is often useful to enhance insight and understanding.
Depression, anxiety and lupus
Depression and anxiety are the most frequently encountered psychiatric problems in patients with lupus (Wekking 1993) , but there are no specific features that are unique to SLE (Hanly 2005) . The use of different criteria for diagnosis has resulted in a wide prevalence (24-57%) across studies (Brey 2002) . For practical purposes, it is probably most helpful to consider depression and anxiety as dimensions rather than categories (Goldberg 1992) .
† Depression and anxiety in SLE are often accompanied by other problems, such as poor anger control.
In SLE, depression that presents with predomi nantly somatic complaints (e.g. pain and lethargy) may remain undiagnosed as these symptoms over lap those of lupus itself. For medical patients such as those with SLE, the Hamilton Rating Scale for Depression (HRSD) has low sensitivity in detecting depression as its questions are too direct (e.g. have you had suicidal thought in the past 3 weeks?) and are intended for psychiatric patients with clearcut depressive disorder. Most medical patients will get a very low score on the HRSD but this does not mean they are not depressed or have good mental health. Stoll et al (2001) therefore proposed the routine use of the Short Form (SF)-36 to detect depression when assessing patients with SLE. The SF-36 mental health score closely correlates with the severity of depression on the HRSD but its questions are more relevant to the everyday life of people with SLE (e.g. have your physical health or emotional problems interfered with activities like visiting relatives?).
Antidepressants
Data regarding the use of antidepressants in individuals with SLE stem from just a few case reports. Selective serotonin reuptake inhibitors (SSRIs) can be useful in treating depression in NPSLE, and psychiatrists need to be aware of specific sideeffects of different antidepressants. Cassis et al (2005) and Hill et al (1998) have reported erythematosus skin lesions related to bupropion and sertraline use. Fluoxetine can cause extrapyramidal sideeffects (Fallon 1991) . Douglas and colleagues (1982) reported a case of depression caused by lupus cerebritis that was successfully treated by electroconvulsive therapy (ECT). With the development of a variety of anti depressants, the use of ECT to treat depression in people with SLE has become secondline in clinical practice. Nevertheless, ECT does play a role in treating manic psychosis and catatonia stemming from NPSLE (Ditmore 1992) .
The role of psychological therapies and non pharmacological strategies such as CBT, cognitive remediation relaxation therapy, sleep hygiene and regular exercise should also be considered.
Fatigue and lupus
Fatigue has been reported as one of the most common and most disabling symptoms in SLE, with a prevalence of up to 80% (Krupp 1990 ). Eleven per cent of patients in the UK fulfilled the American College of Rheumatology classification criteria for fibromyalgia (Taylor 2000) , a condition characterised by chronic fatigue syndrome for more than 3 months and multiple tender spots.
Case study: Fibromyalgia in SLE
A 50yearold housewife with longstanding SLE has been treated with prednisolone and azathioprine for the past 3 years. She started to complain of easy fatigue, poor sleep and generalised body aches and pains 6 months ago. In addition, she noted † A simplification of the current classifications of mental disorder will be discussed by David Goldberg in the January 2010 issue of Advances. Ed.
Advances in psychiatric treatment (2009) having a dry mouth and dysuria; no other systemic symptoms were observed. Physical examination revealed multiple tender spots over the neck and trunk. Thorough investigation showed no evidence of arthritis and her urine was sterile. Serology revealed no evidence of active lupus and metabolic screening did not suggest electrolyte imbalance or endocr inopat hy. She was refer red by her rheumatologist to a psychiatrist and the diagnosis of fibromyalgia was made. Eight weeks after treatment with fluoxetine, the symptoms of fibromyalgia substantially improved.
Box 4 summarises the key factors that con tribute to fatigue in SLE. Tench et al (2000) have suggested that myalgia and arthralgia related to lupus may disturb sleep, resulting in daytime fatigue. Increased levels of anxiety and depression are also associated with increased SLErelated fatigue (Ward 2002) .
Clinical assessment
Symptoms of fatigue can be rated using the Fatigue Severity Score developed by Krupp et al (1990) . It is also worth considering laboratory tests to rule out underlying medical conditions such as anaemia, hypothyroidism and malignancies.
Treatment
Treatment of fatigue in individuals with SLE is mainly symptomatic. Concomitant depressive disorder and sleep disturbance which may lead to fatigue should be identified and treated (McKinley 1995) . An SSRI such as fluoxetine may improve mood and energy levels.
Psychological interventions such as lifestyle changes, including sleep hygiene, relaxation and regular exercise programmes, are safe and helpful. Psychological interventions such as lifestyle changes, including sleep hygiene, relaxation and regular exercise programmes, are safe and helpful. Tench et al (2003) conducted a randomised controlled trial in which patients with SLE were assigned to a 12week programme of aerobic exercise, relaxation therapy or no intervention. At the end of the 12 weeks they compared the participants' physiological, symptomatic and functional changes. Graded exercise led to significantly greater overall improvement than relaxation therapy or no intervention.
The role of the psychiatrist
In and outpatient referrals are the usual routes by which rheumatologists obtain psychiatric opinions on patients with NPSLE, but they have insufficient facetoface communication with psychiatrists. In the consultation-liaison model of practice, however, psychiatrists attend ward rounds and discuss the diagnosis and management plan with the rheumatology team. The advantages of this include better communication, which allows the psychiatrist a broader view, clarifies uncertainties and leads to agreement on the diagnosis. It may involve a longitudinal followup to address difficult issues and review responses to various treatment strategies. The psychiatrist needs to formulate a framework for assessing patients with NPSLE. The psychiatrist's role in the management of NPSLE is summarised in Box 5.
Conclusions
Psychiatric symptoms often occur in patients with SLE. Although the American College of Rheuma tology nomenclature for NPSLE is comprehensive, psychiatric symptoms described in individuals with SLE are neither sensitive nor specific. Prompt recognition of psychiatric symptoms, with exclu sion of aetiologies such as infection, metabolic or endocrine dysfunction and drug intoxication, is absolutely necessary.
Further research is required to explore the possi bility of using antineuronal antibodies, electro neurophysiological studies and diffusion BOx 5 The psychiatrist's role in the management of NPSLE tensor imaging in diagnosing NPSLE, and to assess the efficacy of psychotropic medication and psychotherapy.
Close liaison between psychiatrist s and rheumatologists undoubtedly facilitates effective assessment and management of the disease, which can improve the quality of life of individuals with SLE and associated psychiatric syndromes.
EMI answers 1 f 4 g 7 n 2 c 5 h 8 m 3 e 6 k 9 q
